Slingshot members are tracking this event:
Sage Therapeutics (SAGE) Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders
Slingshot Insights Explained
Dec 19, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Sage-217, Mood Disorders, Phase 2